141 related articles for article (PubMed ID: 22714719)
1. Clinical trials for predictive medicine.
Simon R
Stat Med; 2012 Nov; 31(25):3031-40. PubMed ID: 22714719
[TBL] [Abstract][Full Text] [Related]
2. Drug-diagnostics co-development in oncology.
Simon R
Front Oncol; 2013 Dec; 3():315. PubMed ID: 24392354
[TBL] [Abstract][Full Text] [Related]
3. Biomarker based clinical trial design.
Simon R
Chin Clin Oncol; 2014 Sep; 3(3):39. PubMed ID: 25841465
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials for predictive medicine: new challenges and paradigms.
Simon R
Clin Trials; 2010 Oct; 7(5):516-24. PubMed ID: 20338899
[TBL] [Abstract][Full Text] [Related]
5. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
6. On the efficiency of targeted clinical trials.
Maitournam A; Simon R
Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
[TBL] [Abstract][Full Text] [Related]
7. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.
Shi Q; Mandrekar SJ; Sargent DJ
Scand J Gastroenterol; 2012 Mar; 47(3):356-62. PubMed ID: 22181041
[TBL] [Abstract][Full Text] [Related]
10. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
11. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
12. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
14. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
15. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.
Lienhardt C; Davies G
Int J Tuberc Lung Dis; 2010 May; 14(5):528-37. PubMed ID: 20392344
[TBL] [Abstract][Full Text] [Related]
16. The cross-validated adaptive signature design.
Freidlin B; Jiang W; Simon R
Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
[TBL] [Abstract][Full Text] [Related]
17. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
18. The efficiency of clinical trial designs for predictive biomarker validation.
Young KY; Laird A; Zhou XH
Clin Trials; 2010 Oct; 7(5):557-66. PubMed ID: 20571132
[TBL] [Abstract][Full Text] [Related]
19. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
20. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]